Hepatic insulin resistance and increased gluconeogenesis are known therapeutic targets of metformin, but the role of hepatic glycogen in the pathogenesis of diabetes is less clear. Mouse model of neuropeptide Y (NPY) overexpression in noradrenergic neurons (OE-NPY DbH ) with a phenotype of late onset obesity, hepatosteatosis, and prediabetes was used to study early changes in glycogen structure and metabolism preceding prediabetes. Furthermore, the effect of the anti-hyperglycemic agent, metformin (300 mg/kg/day/4 weeks in drinking water), was assessed on changes in glycogen metabolism, body weight, fat mass, and glucose tolerance. Glycogen structure was characterized by cytofluorometric analysis in isolated hepatocytes and mRNA expression of key enzymes by qPCR. OE-NPY DbH mice displayed decreased labile glycogen fraction relative to stabile fraction (the intermediate form of glycogen) suggesting enhanced glycogen cycling. This was supported by decreased filling of glucose residues in the 10th outer tier of the glycogen molecule, which suggests accelerated glycogen phosphorylation. Metformin reduced fat mass gain in both genotypes, but glucose tolerance was improved mostly in wild-type mice. However, metformin inhibited glycogen accumulation and normalized the ratio between glycogen structures in OE-NPY DbH mice indicating decreased glycogen synthesis. Furthermore, the presence of glucose residues in the 11th tier together with decreased glycogen phosphorylase expression suggested inhibition of glycogen degradation. In conclusion, structural changes in glycogen of OE-NPY DbH mice point to increased glycogen metabolism, which may predispose them to prediabetes. Metformin treatment normalizes these changes and suppresses both glycogen synthesis and phosphorylation, which may contribute to its preventive effect on the onset of diabetes.
| INTRODUCTION
Type 2 diabetes (T2D) is a complex disorder of glucose metabolism characterized by insulin resistance (IR) , that leads to compensatory hyperinsulinemia and increased hepatic glucose output resulting in decreased glucose uptake in insulin-sensitive tissues (liver, skeletal muscle, and adipose tissue) and increased hepatic glucose production. Glucose is stored in tissues as glycogen, but liver is the only organ capable of producing glucose from glycogen (reviewed by Kowalski et al 1 ). The role of hepatic glycogen in the pathogenesis of diabetes is controversial and unclear in many aspects.
2-5 However, increased glycogenolysis and glycogen cycling have been associated with diabetes in both rodents and humans. 6, 7 Fitting with this, it has been suggested that glycogen degrades more rapidly in T2D, which could explain the uncontrolled hepatic glucose output. 8 The liver glycogen is stored in the form of individual molecules (full-size glycogen molecules, b-particles), which construct larger aparticle conglomerates consisting of 20-40 b-particles. [9] [10] [11] Individual glycogen molecules are composed of 2 fractions with different solubility in trichloroacetic acid (TCA): a highly soluble labile glycogen fraction (LF; lyoglycogen), which forms the 4 outer tiers of glycogen particles, and a less metabolically active form, stabile glycogen fraction (SF; desmoglycogen). 12 It has been under debate whether the labile glycogen corresponds to larger glycogen particles (with molecular mass of~10 7 Da) and the stabile glycogen to smaller protein (glycogenin)-binding particles (with mass of~4 9 10 5 Da), and about their actual physiological meanings. [13] [14] [15] [16] However, there is an agreement on the existence of glycogen particles with different solubility in TCA, and that changes occur in the ratio of the labile and stabile structures (LF/SF ratio) in different physiological and pathological conditions. 17 In a physiological glycogen synthesis, when fasted animals are administered with glucose, the stabile fraction is initially quickly increased, but then the labile fraction increases being responsible for the actual glycogen accumulation. 18 In contrast, in a pathologic situation of liver cirrhosis, the stabile fraction is especially increased and the ratio of LF/SF decreased, suggesting a more stable increase in glycogen. [19] [20] [21] [22] It can be hypothesized that similar molecular changes in glycogen structure could also occur in diabetes, as similar disruptions in glycogen metabolism have been shown to occur in cirrhosis and diabetes, 23 and a-particles of glycogen have been shown to degrade more readily in diabetes. 8 However, it is not known whether the structural changes contribute to the disease pathogenesis, and whether these changes could be targeted by drug therapy.
The aim of this study was to characterize the hepatic glycogen structure and metabolism in a state preceding disruptions in glucose metabolism, and after metformin therapy. induced by high caloric diet and low-dose streptozotocin. [24] [25] [26] Hepatic accumulation of triglycerides and glycogen seem to play an important role in the development of prediabetes and streptozotocin-induced diabetes in the model. 24 Our previous findings suggest that increased glycogen cycling precedes glycogen accumulation, but it is not known, whether the changes are detected also in the glycogen structure. Furthermore, we chose metformin as the reference drug, because the main mechanism of its anti-hyperglycemic effect is to decrease hepatic glucose production, and as it has been shown to attenuate the progression of prediabetes to diabetes.
27-29
2 | MATERIALS AND METHODS
| Animals
Homozygous male OE-NPY DbH mice (n = 9-11/group) were used in this study with their wild-type (WT) controls. Generation of the transgenic homozygous OE-NPY DbH mice, maintained on a C57BL/ 6N inbred background, and their metabolic phenotype have been described in detail previously. 24, 26 The age of the mice in the current experiment was 4 months at the initiation of metformin treatment, which is the borderline age when the first signs of IR (ie, increased glucose-stimulated insulinemia and IGT) start to emerge eventually leading to clear prediabetic phenotype at the age of 7 months.
| Study protocol
The study was authorized by the Finnish National Animal Experiment 
| Hepatocyte isolation and structure analysis
Hepatocyte isolation was performed according to Kudryavtseva et al. 30 Mouse liver (n = 3-7/group) was perfused for 10 minutes in a K,Na-phosphate-sucrose buffer I, pH = 7.8 (475 mL Na 2 HPO 4 9 2H 2 O, 25 mL KH 2 PO 4 , 500 mL sucrose). A piece of liver was placed into buffer I for 20 min, and further a 2 9 2 9 2 mm piece was incubated in a phosphate buffer II, pH = 7.2 (400 mL Na 2 HPO 4 9 2H 2 O, 100 mL KH 2 PO 4 ) for 5 min- Germany), a Plan NEOFLUAR 40 9 0.75 lens, and a DFC360 FX digital high-sensitivity CCD camera (1392 9 1400). To excite, Au-SO 2 and EtBr-SO 2 fluorescence interference filters at 450-490 and 546 nm were used, and to record fluorescence interference filters at 515-565 and 590 nm were used, respectively. The intensity of fluorescence of the cells stained with Au-SO 2 and EtBr-SO 2 was measured using ImageJ software (National Institute of Health, USA). The total glycogen content (TGC) in each cell was taken to be equal to the sum of glycogen fractions. The fluorescence of 100 cells was measured for each preparation. The relative number of glucose residues in the outer tiers of the glycogen molecule was calculated using the data on the number of glucose chains that were calculated according to the theoretical formulations of the Whelan's model. 33 As labile fraction constitutes the first 8 tiers of the glycogen molecule and consists of 255 glucose chains, it has been accepted that the LF/SF ratio that is ≤ 1 corresponds to the ninth tier, the LF/SF ratio that is ≤ 2 corresponds to the 10th tier, LF/SF ratio that is ≤ 4 corresponds to the 11th tier, and LF/SF ratio that is ≤ 8 corresponds to the 12th end tier of the molecule.
| Gene expression analyses
Samples for RNA isolation (n = 9-11/group) were stored in RNA Sta- 
| Statistical analysis
Statistical processing of glycogen contents were analyzed with Student's t test, using SigmaPlot v 11.0 software (Systat Software Inc., San Jose, CA). All the other parameters were analyzed with GraphPad Prism 6.0 software (GraphPad Software, Inc., San Diego, CA).
Tests with multiple time points were analyzed with repeated measures two-way ANOVA. Parameters with single time points were analyzed with two-way ANOVA taking into account the genotype and drug effects, and their interaction, and were followed by Bonferroni post hoc tests when interaction was significant. The results are expressed as means AE SEM. P < .05 was considered statistically significant.
3 | RESULTS
| Body composition and food intake
OE-NPY DbH mice in this study, in contrast to previous reports, were similar in body weight and adiposity compared to WT mice AILANEN ET AL. (Table 2) .
| Glucose metabolism
TGC correlated significantly with both the labile (r = .933, P < .001) 
| Effects of metformin on glycogen structure
In order to study whether metformin influences the glycogen content or structure, TGC and different glycogen fractions were analyzed from OE-NPY DbH and WT mice receiving metformin for 4 weeks, and compared to control groups. There was no change in glycogen content or structure in WT mice between the treatments. However, metformin treatment markedly decreased the content of the stabile fraction and significantly also the content of the labile fraction in OE-NPY DbH resulting in reduced TGC and normalization of the LF/SF ratio to the level of the WT group (Table 1) . Furthermore, the composition of glycogen residues to the 11th tier of glycogen molecule was present in metformin-treated OE-NPY DbH mice pointing to a decreased glycogen phosphorylase activity as glycogen phosphorylase is responsible for degradation of upper tiers of glycogen molecules (Table 2 ). In accordance, mRNA expression of glycogen phosphorylase (Pygl) was significantly decreased in metformin-treated OE-NPY DbH mice. No differences were detected in WT mice, between genotypes in controltreated mice, or in glycogen synthase (Gys) expression between the treatment groups ( Figure 4A -B).
| DISCUSSION
Metformin is the first-line anti-diabetic agent to treat T2D, but multiple studies have shown that metformin is also effective in preventing or delaying the onset of T2D. [27] [28] [29] Metformin improves insulin sensitivity by decreasing hepatic glucose production due to decreased ATP availability, 6, 34 but also several other contributing mechanisms have been reported. [35] [36] [37] The roles of gluconeogenesis as a source of hepatic glucose overproduction and as a target of metformin action are well described, but less is known about the role of changes in glycogen structure and metabolism, especially in prediabetic state. In this study, we show that early phase changes in glycogen structure may contribute to the development of IGT and diabetes, and treatment with metformin in this early phase decreases hepatic glycogen levels and normalizes glycogen structure, which may have therapeutic relevance in prevention of the onset of prediabetes or diabetes. 
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The glycogen structure was elucidated in a genetically modified mouse model of prediabetes, OE-NPY DbH mouse, at an age prior to manifestation of overt IGT in order to evaluate our previous findings of increased hepatic glycogen cycling (ie, increased mRNA expression of glycogen synthase and phosphorylase) preceding glycogen accumulation. 24 Despite equal glycogen contents and similar glucose tolerance between the genotypes, changes in the molecular structure of glycogen in OE-NPY DbH hepatocytes, that is, increased content of the stabile fraction and decreased content of the labile fraction supported by decreased filling of the 10th tier in the glycogen molecules, suggest that increased glycogen synthesis and degradation takes place before prediabetes. Using the same cytofluorometric analysis similar changes in glycogen structure were detected in The data are represented as mean AE SEM (n = 3 mice/group). SF, stabile fraction; LF, labile fraction; TGC, total glycogen content; Met, metformin-treated group. **P < .01 and ***P < .001 compared to WT mice receiving drinking water without metformin (Ctr), and #P < .05, ###P < .001 compared to OE-NPY DbH mice receiving drinking water without metformin (Ctr) with Student's t test. another chronic pathologic condition, liver cirrhosis. 18, 19 This is opposite to the situation of physiological glycogen synthesis, (eg, in glucose administration after a prolonged fast), where the metabolically active form, labile glycogen, is rapidly increased. 18, 38 Previous data on glycogen structure and metabolism in prediabetes is scarce, but increased glycogen metabolism has also been reported in prediabetic Zucker (fa/fa) rats. 39 In T2D, glycogen metabolism has received more attention, showing increased glycogen metabolism 6, 7, 40 and fragility of the a-particles of glycogen. 3, 8, 40 However, as the glycogen content in diabetes varies between the studies 5,41-43 depending on the type (1 or 2) and the state (early or established) of diabetes, and the diurnal cycle, 7, 40, 44 accelerated glycogen metabolism and the structure of glycogen molecules seem to be better biomarkers for pathogenic glucose metabolism than the glycogen content itself.
T A B L E 3
We next studied the effect of metformin on hepatic glycogen structure. In OE-NPY DbH hepatocytes, metformin decreased the contents of total and both structural forms of glycogen. Furthermore, supported by decreased Pygl mRNA expression, increased LF/SF ratio and filling of the 11th tier in the glycogen molecule indicate that glycogen phosphorylase activity was inhibited. When glycogen phosphorylase does not decompose glycogen fast enough and there is no formation of new molecules, glycogen synthase and the branching enzyme attach glucose residues to glycogen molecules that are already formed. As the overall glycogen content was decreased, it seems that also glycogen synthesis was decreased by metformin. Our results reinforce the previous finding of metformin's ability to reduce glycogen degradation. [45] [46] [47] However, we show that this is the case already in an early phase, before the actual symptoms of IGT. Therefore, this could be a mechanism of action in decreasing hepatic glucose output especially in a situation of prediabetic enhancement of glycogen accumulation and cycling. Inhibition of glycogen phosphorylase activity is known to improve glucose metabolism and has previously been studied as a potential drug target for treating hyperglycemia. [48] [49] [50] Furthermore, metformin's ability to inhibit glycogen synthesis has previously been suggested by others, [51] [52] [53] although opposite findings also occur. 47 Similar to diabetes, the results on metformin-induced changes in total hepatic glycogen content have been more controversial and depended on the model used (ie, severity of the disease and in vivo or in vitro study). 46, 47, 51 Although potentially beneficial changes in glycogen metabolism were detected in metformin-treated OE-NPY DbH mice, glucose tolerance was not markedly improved, which is not unexpected in glucose-tolerant mice. 54 Instead, metformin-treated WT mice displayed mild improvement in glucose tolerance, possibly due to decreased visceral adiposity, as no response in glycogen structure was 
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